Pleural
Identification of a Five-Gene Signature for Predicting Survival in Malignant Pleural Mesothelioma Patients
Frontiers in Genetics 2020 August 7 [Link] Yiyang Bai, Xiao Wang, Jia Hou, Luying Geng, Xuan Liang, Zhiping Ruan, Hui Guo, Kejun Nan, Lili Jiang Abstract Malignant pleural mesothelioma (MPM), predominantly caused by asbestos exposure, is a highly aggressive cancer with poor prognosis. The staging systems currently used in clinics is inadequate in evaluating the…
Read MoreSystematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma
Cancers 2020 August 17 [Link] Haitang Yang, Duo Xu, Zhang Yang, Feng Yao, Heng Zhao, Ralph A Schmid, Ren-Wang Peng Abstract Background: Malignant pleural mesothelioma (MPM) is driven by the inactivation of tumor suppressor genes (TSGs). An unmet need in the field is the translation of the genomic landscape into effective TSG-specific therapies. Methods: We…
Read MoreEvolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment
Clinical Cancer Research 2020 August 14 [Link] Runzhe Chen, Won-Chul Lee, Junya Fujimoto, Jun Li, Xin Hu, Reza Mehran, David Rice, Stephen G Swisher, Boris Sepesi, Hai T Tran, Chi-Wan Chow, Latasha D Little, Curtis Gumbs, Cara Haymaker, John V Heymach, Ignacio I Wistuba, J Jack Lee, P Andrew Futreal, Jianhua Zhang, Alexandre Reuben, Anne…
Read MoreInitial clinical experience treating patients with palliative radiotherapy for malignant pleural mesothelioma on the HalcyonTM linear accelerator
Annals of Palliative Medicine 2020 August 14 [Link] Andrew R Barsky, Michele M Kim, Russell Maxwell, Amberly Mendes, Christopher M Wright, Emily J Anstadt, Sally McNulty, Lei Dong, James M Metz, Steven J Feigenberg, Taoran Li, Keith A Cengel Abstract Background: Radiation therapy (RT) can provide effective symptomatic palliation in patients with malignant pleural mesothelioma…
Read MoreSymptom Burden and Unmet Needs in MPM: Exploratory Analyses From the RESPECT-Meso Study
Journal of Palliative Care 2020 August 14 [Link] Siao Nge Hoon, Iain Lawrie, Cathy Qi, Najib Rahman, Nick Maskell, Karen Forbes, Stephen Gerry, Leanne Monterosso, Anoop Chauhan, Fraser J H Brims Abstract Objective: Malignant Pleural Mesothelioma (MPM) has a poor prognosis and high symptom burden. RESPECT-Meso was a multicenter randomized study examining the role of…
Read MoreUsing creative co-design to develop a decision support tool for people with malignant pleural effusion
BMC Medical Informatics and Decision Making 2020 August 5 [Link] Cheryl Grindell, Angela Tod, Remi Bec, Daniel Wolstenholme, Rahul Bhatnagar, Parthipan Sivakumar, Anna Morley, Jayne Holme, Judith Lyons, Maryam Ahmed, Susan Jackson, Deirdre Wallace, Farinaz Noorzad, Meera Kamalanathan, Liju Ahmed, Mathew Evison Abstract Background: Malignant pleural effusion (MPE) is a common, serious problem predominantly seen…
Read MoreTrabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study
Clinical Lung Cancer 2020 July 3 [Link] Diego Cortinovis, Federica Grosso, Luciano Carlucci, Paolo Andrea Zucali, Giulia Pasello, Marcello Tiseo, Francesca Sperandi, Lital Hollander, Francesca Galli, Valter Torri, Eliana Rulli, Stefania Canova, Antonio Maconi, Paolo Bidoli, Giovanni Luca Ceresoli , Maurizio D’Incalci, ATREUS investigators Abstract Introduction: New therapeutic approaches in unresectable malignant pleural mesothelioma (MPM)…
Read MoreVerification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma
Cancer Epidemiology, Biomarkers, and Prevention 2020 July 30 [Link] Ferdinando Cerciello, Meena Choi, Sara L Sinicropi-Yao, Katie Lomeo, Joseph M Amann, Emanuela Felley-Bosco, Rolf A Stahel, Bruce W S Robinson, Jenette Creaney, Harvey I Pass, Olga Vitek, David P Carbone Abstract Background: We have verified a mass spectrometry (MS)-based targeted proteomics signature for the detection…
Read MoreDeterminants of plasma calretinin in patients with malignant pleural mesothelioma
BMC Research Notes 2020 July 29 [Link] Martin Lehnert, Daniel G Weber, Dirk Taeger, Irina Raiko, Jens Kollmeier, Susann Stephan-Falkenau, Thomas Brüning, Georg Johnen, MoMar-Study Group Abstract Objective: Calretinin is a well-known immunohistochemical tissue marker in the diagnosis of malignant mesothelioma. Promising results also indicate the use in early detection. In the present cross-sectional survey,…
Read MoreRandomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901
Clinical Lung Cancer 2020 July 3 [Link] Arkadiusz Z Dudek, Xiaofei Wang, Lin Gu, Stephanie Duong, Thomas E Stinchcombe, Robert Kratzke, Hossein Borghaei, Everett E Vokes, Hedy L Kindler Abstract Background: The role of maintenance therapy for malignant pleural mesothelioma (MPM) is unknown. We performed a randomized phase II trial to determine if continuation of…
Read More